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ABSTRACT:
Expression of the long noncoding RNA (lncRNA) SPRY4-IT1 is low in normal 
human melanocytes but high in melanoma cells. siRNA knockdown of SPRY4-
IT1 blocks melanoma cell invasion and proliferation, and increases apoptosis. To 
investigate its function further, we affinity purified SPRY4-IT1 from melanoma 
cells and used mass spectrometry to identify the protein lipin 2, an enzyme that 
converts phosphatidate to diacylglycerol (DAG), as a major binding partner. SPRY4-
IT1 knockdown increases the accumulation of lipin2 protein and upregulate the 
expression of diacylglycerol O-acyltransferase 2 (DGAT2) an enzyme involved in 
the conversion of DAG to triacylglycerol (TAG). When SPRY4-IT1 knockdown and 
control melanoma cells were subjected to shotgun lipidomics, an MS-based assay that 
permits the quantification of changes in the cellular lipid profile, we found that SPRY4-
IT1 knockdown induced significant changes in a number of lipid species, including 
increased acyl carnitine, fatty acyl chains, and triacylglycerol (TAG). Together, these 
results suggest the possibility that SPRY4-IT1 knockdown may induce apoptosis via 
lipin 2-mediated alterations in lipid metabolism leading to cellular lipotoxicity. 
INTRODUCTION
Eukaryotic genomes express a complex repertoire 
of thousands of RNAs that lack protein-coding capacity 
[1, 2]. These noncoding RNAs (ncRNAs) are broadly 
classified as long or small based on a nucleotide length 
of >200 or <200 nucleotides (nt), respectively. Small 
regulatory ncRNAs are commonly conserved and are 
involved in transcriptional and posttranscriptional gene 
regulation through specific base pairing with their target 
genes or transcripts. In contrast, long noncoding RNAs 
(lncRNAs) are less well conserved and regulate gene 
expression by diverse mechanisms, including epigenetic 
mechanisms, that remain incompletely understood [3-6]. 
LncRNAs may be derived from genomic sequences that 
are intergenic, intronic, overlapping, or antisense with 
respect to nearby protein-coding genes, and although some 
lncRNAs may be translated into short polypeptides, the 
vast majority are rarely or never translated [7, 8]. 
Until recently, lncRNAs were frequently dismissed 
as non-functional transcriptional ‘‘noise’’ [9]. However, 
the past few years have seen a rapid increase in our 
understanding of the regulatory functions of lncRNAs 
and their role in human disease and development [10, 
11]. LncRNAs exhibit exquisite context-dependency 
commensurate with their presumed regulatory role, with 
cell type-specific expression and localization to discrete 
subcellular compartments [12-14]. At the molecular level, 
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lncRNAs influence target gene expression at specific 
genomic loci by directly interacting with chromatin 
regulatory proteins and/or by modulating the activity 
of their interacting partners [15-20]. LncRNAs can 
function as decoys for bound proteins and can also alter 
the structure and function of the protein [17]. Although 
lncRNAs play physiological roles during normal cellular 
development and differentiation [21], changes in their 
expression are associated with several diseases, including 
cancer, heart disease, Alzheimer’s disease, psoriasis, 
and spinocerebellar ataxia type 8 [22]. Accumulating 
evidence suggests that lncRNAs may also play a role 
in tumorigenesis. For example, increased expression of 
HOTAIR is associated with poor prognosis in pancreatic 
cancer [23], and increased expression of PCGEM1 and 
PCA3/DD3 is associated with a high risk of developing 
prostate cancer [24]. 
Recently, we identified a number of lncRNAs that 
are differentially expressed in melanoma cell lines relative 
to melanocytes and keratinocytes [14, 25]. One of these, 
SPRY4-IT1 (Sprouty4-Intron 1; GenBank accession 
ID AK024556), is highly expressed in melanoma cells 
relative to melanocytes, and is localized predominantly in 
the cytoplasm. Previously we showed that SPRY4-IT1 is 
derived from the intronic region of the SPRY4 gene and 
that its predicted secondary structure contains several long 
hairpins [14]. Moreover, RNAi-mediated knockdown of 
SPRY4-IT1 inhibited invasion and proliferation and 
induced apoptosis of melanoma cells, suggesting an 
important role for this lncRNA in melanoma biology. 
In the present study, we sought to identify SPRY4-
IT1-interacting proteins and elucidate this lncRNA’s 
molecular function. In melanoma cells, SPRY4-IT1 
transcripts are processed in the nucleus prior to transport 
to the cytoplasm, where they are primarily located in 
polysomes. We also identify the phosphatidate lipin 2 as 
a major SPRY4-IT1-binding protein, and demonstrate the 
existence of a novel lipid regulatory mechanism involving 
SPRY4-IT1 and lipin 2. Our results are consistent with 
the possibility that SPRY4-IT1 knockdown may induce 
apoptosis via lipin 2-mediated alterations in lipid 
metabolism leading to cellular lipotoxicity. Together these 
results provide novel insight into the mechanisms by 
which extranuclear processing of lncRNAs contributes to 
melanoma biology.
RESULTS
Processing of SPRY4-IT1 Transcripts
SPRY4-IT1 was originally identified as a 706 bp 
transcript in adipose tissue as part of a large-scale cDNA 
sequencing study [26]. The SPRY4-IT1 sequence was 
shown by PCR to initiate in intron 1 of the SPRY4 gene 
and extend to exon 3 (Fig. 1A). Interestingly, the 5′ region 
of the full-length SPRY4-IT1 transcript was detected in 
samples of nuclear, but not cytoplasmic RNA, suggesting 
that the processing of SPRY4-IT1 takes place before 
nucleocytoplasmic export (Fig. 1B). We confirmed using 
5′ RACE that the first 244 nt of the 5′ sequence is missing 
from cytoplasmic SPRY4-IT1 (Fig. S1). To validate this 
observation and to visualize the subcellular localization 
of SPRY4-IT1, we designed several RNA-FISH probes 
specific for the 3′ or 5′ regions of SPRY4-IT1. This analysis 
confirmed the presence of the full-length transcript in the 
nucleus but not in the cytoplasm (Fig. S2), in agreement 
with PCR results. SPRY4-IT1 staining in melanocytes is 
mainly localized to the nucleus and this may be the reason 
of intense nuclear staining in melanocytes. Together 
these data demonstrate that the SPRY4-IT1 transcript 
undergoes maturation by cleavage of the 5’ region prior 
to its transport to the cytoplasm. This may suggest that 
the regulation of the 5’ cleavage controls the export of 
the transcript to the cytoplasm thus, the overall SPRY4-
IT1 content may depend on the efficiency of the nuclear 
excision event. 
Although the precise 3′ termination site of the 
SPRY4-IT1 transcript is not yet known, northern 
blot analysis shows a SPRY4-IT1 transcript size of 
approximately 1.8 kb (Fig. 1C), and the 3′ sequence of the 
transcript is very similar to that of Exon 3 of the SPRY4 
gene. Therefore, we propose that SPRY4-IT1 carries both 
intronic and exonic sequences and can be considered a 
noncoding splice variant of the SPRY4 gene. 
SPRY4-IT1 and SPRY4 Gene Transcripts 
Function Independently 
We next asked whether the transcription and 
function of SPRY4-IT1 and SPRY4 are coordinately or 
independently regulated. Despite the similar expression 
patterns of SPRY4 and SPRY4-IT1, siRNA-mediated 
knockdown of SPRY4 (siRNA targeting exon 1) in A375 
melanoma cells reduced the expression of SPRY4 but not 
SPRY4-IT1 (Fig. 1D), demonstrating that transcription 
of the coding (SPRY4) and noncoding (SPRY4-IT1) 
genes occurred independently. To confirm this in a more 
physiological setting, we treated melanocytes (low 
expression of SPRY4-IT1) with fibroblast growth factor 2 
(FGF2), which is known to induce SPRY4 expression [27]. 
In serum-containing medium, FGF2 induced expression 
of SPRY4-IT1 and SPRY4 to similar extents (Fig. 2A). 
However, SPRY4-IT1 transcription was further elevated 
in melanocytes treated with FGF2 in serum-free medium 
(Fig. 2B), confirming independent transcription of SPRY4-
IT1 and SPRY4. These results suggest that SPRY4-IT1 
responds to starvation and general stress responses. 
To determine whether the stability of SPRY4-IT1 and 
SPRY4 transcripts is independently regulated, we treated 
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Figure 1:Maturation and Cellular Compartmentalization of SPRY4-IT1 Transcripts. (A) The sequence and location of 
SPRY4 and SPRY4-IT1. SPRY4-IT1 is embedded in the SPRY4 parent transcript. SPRY4-IT1 starts in the first intron of the SPRY4 gene and 
extends up to exon 3. 5′ RACE shows the maturation and cleavage of a 244 nt transcript in the 5′ region of SPRY4-IT1. (B) Detection of 
nuclear and cytoplasmic forms of SPRY4-IT1. (C) Northern blot analysis shows the sizes of SPRY4 (4.9 kb) and SPRY4-IT1 (1.8 kb). The 
SPRY4 exon 1 probe hybridizes specifically to SPRY4, but the SPRY4 exon 3 probes recognize both SPRY4 and SPRY4-IT. (D) SPRY4 exon 
1 siRNA knocks down the expression of SPRY4, but not SPRY4-IT1, in A375 melanoma cells. 
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A375 cells with the polymerase II transcriptional inhibitor 
α-amanitin and measured the transcript levels by RT-
PCR. We observed that SPRY4 RNA decayed faster than 
SPRY4-IT1 in both the nucleus and cytoplasm, supporting 
the functional independence of the transcripts (Fig. S3). 
Finally, we independently knocked down SPRY4 and 
SPRY4-IT1 in A375 cells using transcript-specific siRNAs. 
Confirming our previous report [14], A375 cell invasion 
was inhibited ~50% by SPRY4-IT1 knockdown but was 
unaffected by SPRY4 silencing (Fig. S4A). Similarly, 
SPRY4-IT1 silencing induced apoptosis of A375, as 
measured by caspase 3 activity, more effectively than did 
SPRY4 knockdown (Fig. S4B). Collectively, these data 
establish the transcriptional and functional independence 
of SPRY4-IT1 and its host gene SPRY4. 
SPRY4-IT1 Is Localized to the Polysome Fraction 
and Binds the Lipid Phosphatase Lipin 2 
In a recent ribosomal footprint study, Ingolia et al. 
[28] reported that cytoplasmic lncRNAs are primarily 
found in ribosomal clusters or polysomes. To determine 
the location of SPRY4-IT1, we used density gradient 
centrifugation to isolate monosomal and polysomal 
fractions from A375 cells and recovered 13 fractions: 
2 monosomal and 11 polysomal (Fig. 3A). Total RNA 
was isolated from the individual fractions and analyzed 
for the presence of SPRY4-IT1 by northern blotting. 
SPRY4-IT1 was detected only in polysomal fractions 
3 through 9 (Fig. 3B), indicating that SPRY4-IT1 is 
indeed associated with polysomes and is not retained in 
monosomes, consistent with the findings of Ingolia et al. 
[28]. Sequence analysis further confirmed that SPRY4-IT1 
Figure 2: SPRY4 and SPRY4-IT1 Are Coordinately Regulated in Melanocytes. Relative expression of SPRY4-IT1 and SPRY4 
following induction by FGF2. Melanocytes were treated with 10 ng/ml FGF2 for 1 or 2 h in the presence or absence of FBS, and the fold 
change in expression of SPRY4 (A) and SPRY4-IT1 (B) was measured by qPCR
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does not show any coding potential; understanding its role 
in possible translational regulation is an ongoing study in 
our laboratory.
We next sought to identify SPRY4-IT1-binding 
proteins in melanoma cells. For this, we affinity purified 
endogenous SPRY4-IT1 from crosslinked A375 lysate 
(Fig. 4A) and interrogated the SPRY4-IT1-associated 
proteins by mass spectrometry (MS). A group of candidate 
proteins was identified and quantified by spectral counting 
(Table S1). The most abundant protein candidate was 
lipin 2 [29], a phosphatidic acid phosphatase (PAP) that 
converts phosphatidate into diacylglycerol (DAG). Lipin 
2 was pulled down specifically with SPRY4-IT1 but not 
with scrambled (control) probes. To verify the physical 
association between lipin 2 and SPRY4-IT1, lipin 2 was 
immunoprecipitated, and associated RNAs were isolated 
and interrogated for the presence of SPRY4-IT1 by qPCR. 
As shown in Figure 4B, SPRY4-IT1 transcripts were 
enriched in anti-lipin 2 immunoprecipitated compared 
with control IgG. 
We next investigated the functional significance 
of the association between SPRY4-IT1 and lipin 2 in 
melanoma cells using gene-specific RNAi. Knockdown of 
lipin 2 with two independent siRNAs led to a concurrent 
loss of SPRY4-IT1 (Fig. 4C). This result suggests that 
the loss of lipin 2 most likely destabilizes SPRY4-IT1. In 
contrast, knockdown of SPRY4-IT1 increased both lipin 
2 mRNA and protein by ~2.5-fold (Fig. 4D and 4F). PAP 
enzymatic activity was markedly increased in SPRY4-
IT1 knockdown cells (Fig. 4E). Given that SPRY4-IT1 
knockdown had no effect on lipin 1 expression (Fig. S5), 
these data suggest that the increased PAP activity in these 
cells is due to the increased abundance of lipin 2. It is 
worth noting that knockdown of the SPRY4 gene did not 
affect the expression of either SPRY4-IT1 or lipin 2 (Fig. 
4). 
SPRY4-IT1 Knockdown Increases Triacylglycerol 
Production via Lipin 2 
To investigate the effect of SPRY4-IT1 modulation of 
lipin 2 expression on global lipid metabolism in melanoma 
cells, we subjected SPRY4-IT1 knockdown and control 
A375 cells to shotgun lipidomics, an MS-based assay that 
permits the quantification of changes in the cellular lipid 
profile (Table S2). We found that SPRY4-IT1 knockdown 
induced significant changes in a number of lipid species, 
Figure 3: SPRY4-IT1 Accumulates in Polysomes and Is Absent from Monosomes. (A) Density gradient fractionation of 
monosome and polysome peaks. (B) Northern blot analysis showing SPRY4-IT1 probe hybridization to RNA isolated from polysomes but 
not monosomes. A GAPDH probe served as a control. Separate blots were prepared to probe SPRY4-IT1 and control (GAPDH) due to 
concerns of overlap in fragment size. L= RNA size marker.
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including increased acyl carnitines (+80.21%), fatty acyl 
chains (+14.24%), and triacylglycerol (TAG) (+15.02%), 
as well as decreased phosphatidic acid (-37.72%), 
phosphatidylcholine (-35.58%), phosphatidylinositol 
(-27.78%), and phosphatidylserine (-26.40%). 
Interestingly, DAG content was decreased despite the 
increase in TAG levels. Since DAG is required for 
TAG synthesis, we hypothesized that the reduction in 
DAG levels in SPRY4-IT1 knockdown cells may be due 
to efficient conversion of DAG to TAG. To test this, 
we examined the expression of acyl-CoA:glycerol-3-
phosphate acyltransferase 3 (GPAT3), diacylglycerol 
O-acyltransferase 1 (DGAT1), and diacylglycerol 
O-acyltransferase 2 (DGAT2), since these enzymes 
play essential roles in DAG to TAG conversion. qPCR 
analysis showed that both DGAT2 and GPAT3 mRNA 
levels were increased in SPRY4-IT1 knockdown cells 
(Fig. 5), providing a possible mechanism for the changes 
in DAG and TAG levels in these cells. We postulate that 
one mechanism by which SPRY4-IT1 knockdown induces 
apoptosis could be through lipin 2-mediated lipotoxicity. 
To investigate further, we knocked-down and over-
expressed lipin 2 in A375 cells and measured cell invasion 
efficiency and doubling time. Interestingly, we observed 
Figure 4:SPRY4-IT1 Knockdown Increases Lipin 2 Protein Accumulation in Melanoma Cells. A) Affinity purification 
of SPRY4-IT1 from A375 cell lysates with SPRY4-IT1-specific probes followed by qPCR. SPRY4-IT1 is enriched compared to scrambled 
(control) probes. U1 RNA was used as endogenous control for pull-downs. (B) qPCR validation showing enrichment of SPRY4-IT1 
following immunoprecipitation of A375 cell lysates with lipin 2-specific or control IgG antibodies.  (C) Relative expression of SPRY4-IT1 
in lipin 2 knock-down cells (D) Relative expression of lipin 2 after siRNA-mediated knockdown of SPRY4-IT1, SPRY4 exon 1 or lipin 2. 
(E) Phosphatidic acid phosphatase assay. (F) Western blot analysis of lipin 2 following siRNA-mediated knockdown of SPRY4-IT1 or lipin 
2. All experiments were performed in triplicate.
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that cell doubling time was increased and cell invasion 
was decreased in both knock-down and force-expressed 
cells (Fig. S6A and B). We postulate that lipin 2 levels 
must be maintained on a steady state level in melanoma 
cells, and modulating lipin 2 levels (either an increase 
or decrease) can negatively affect cell physiology. For 
comparison, we subjected the primary melanocyte cell 
line HEM-l to shotgun lipidomics, and compared cellular 
lipid profiles to A375 cells. Interestingly, we found that 
lipid levels were significantly different in these two 
cell types. For an example, phosphatidylethanolamine 
(PE), Phosphatidylserine (PS), Phosphatidic acid (PA), 
Sphingomyelin (SM) were higher in melanocytes, 
compared to melanoma cells (Table S3). Studying the 
role of lipids in melanocyte and melanoma biology is an 
ongoing study in our laboratory.
DISCUSSION
In contrast to small ncRNAs, which are highly 
conserved and play a role in transcriptional and 
posttranscriptional gene silencing through specific base 
pairing, lncRNAs are often poorly conserved (perhaps 
reflecting lineage specificity and/or more plastic structure–
function constraints) and regulate gene expression by 
diverse mechanisms that are not yet fully understood. We 
previously identified the lncRNA SPRY4-IT1, which is 
derived from the intronic region of the Sprouty4 gene, and 
is upregulated in human melanomas compared to normal 
melanocytes and keratinocytes [14]. siRNA-mediated 
knockdown of SPRY4-IT1 in melanoma was shown to 
affect cell proliferation and apoptosis, suggesting that 
high SPRY4-IT1 expression may play an important role 
in the molecular etiology of human melanomas. In this 
study, we sought to probe this further by identifying the 
molecular function of SPRY4-IT1 and elucidating its 
possible molecular function in melanomas.
We found that SPRY4-IT1 is part of a longer 
noncoding transcript that is processed by cleavage of a 
244 nt 5′ fragment prior to transport to the cytoplasm. The 
fate of the 244 nt fragment is unknown, but it is likely to 
be degraded by exo- and endonucleases. The maturation 
of SPRY4-IT1 is similar to the nuclear processing of 
MALAT1 in lung cancer [30]. We also showed that SPRY4 
and SPRY4-IT1 are independent transcripts, although they 
may be regulated by the same transcriptional machinery. 
A recent study classifying lncRNAs according to their 
genomic origin showed they may originate from (a) 
a bidirectional promoter adjacent to a protein-coding 
gene, (b) the 5′ UTR, (c) a retained intron, (d) within 
an intron, (e) the 3′ UTR, (f) an intergenic non-protein-
coding region, (g) antisense to protein-coding genes, or 
(f) a combination of the above [31]. According to this 
classification, SPRY4-IT1 therefore belongs to the group 
of intron-retained lncRNAs.
One of the direct targets of SPRY4-IT1 identified 
in this study is lipin 2, a member of the lipin family 
of phosphatidate phosphatase enzymes [32]. The 
mouse lipin 2 protein has previously been shown to 
be post-transcriptionally regulated [33]. We showed 
that knockdown of SPRY4-IT1 modulates cellular 
concentrations of lipin 2 substrates, including 
phosphatidate, and cells expressing high SPRY4-IT1 
levels, such as melanomas, might thus be expected to 
accumulate lipin 2 substrates. Indeed, increased levels of 
phosphatidate have been linked to certain types of cancers 
through allosteric activation of the molecular target of 
rapamycin (mTOR) [34] and to a possible role for lipin 
2 in statin resistance of colorectal carcinoma cells in 
vitro [35]. It would be of interest to determine whether 
the influence of SPRY4-IT1 on melanocyte and melanoma 
proliferation involves inhibition of lipin 2 activity and/or 
activation of mTOR. 
Our results are the first to demonstrate a role for 
a lncRNA in lipid metabolism in melanoma cells, and 
collectively, the data support the notion that SPRY4-IT1 
may play a critical role in melanocytic transformation.
MATERIAL AND METHODS
Cell Lines 
Human epidermal melanocytes (HEM-l) were 
grown in MelM media containing MelGS growth 
supplements, 0.5% fetal bovine serum (FBS), penicillin, 
and streptomycin. Melanoma cells A375 (stage 4) were 
grown in Complete Tu medium containing a 4:1 mixture of 
MCDB-153 medium with 1.5 mg/ml sodium bicarbonate 
and Leibovitz’s L-15 medium with 2 mM L-glutamine, 
Figure 5: Expression of Diacylglycerol 
O-acyltransferase 2 and (DGAT2) Acyl-coA:glycerol-
3-phosphate Acyltransferase 3 (GPAT3) Following 
SPRY4-IT1 Knockdown. Both DGAT2 (A) and GPAT3 (B) 
mRNA levels are increased upon knockdown of SPRY4-IT1 in 
A375 cells, which may explain the decrease in DAG levels and 
increase in TAG levels observed in these cells (Table S2).
Oncotarget8966www.impactjournals.com/oncotarget
2% FBS, and 1.68 mM CaCl2. Cells were grown at 37°C 
in a humidified 5% CO2 atmosphere. All cell lines were 
obtained from ATCC (http://www.atcc.org). 
Cloning and Identification of 3′ Spliced Forms of 
SPRY4-IT1 
Total RNA was isolated from A375 cells with 
TRIzol (Invitrogen) and reversed transcribed using 
M-MLV reverse transcriptase. The cDNA was used as a 
template for PCR amplification with various 5′ primers 
within SPRY4-IT1 and 3′ primers downstream in the 
SPRY4 locus. Successful amplification was achieved with 
two forward primers: 5′ IT1 (gtagagatgggggtttcatcctgttg), 
which anneals to the first base of SPRY4-IT1, and SPRY4-
IT1 qPCR (gctgagctggtggttgaaaggaatc), which is located 
305 bp within the SPRY4-IT1 sequence. Successful 
amplification at the 3′ end was achieved with the reverse 
primer SPRY4 Exon 3 (gtccgctttgggccggtgg), which is 
located 229 bp into the third exon of SPRY4. Amplification 
was unsuccessful using primers 500 bp downstream of 
this location. PCR products were cloned and sequenced. 
Sequences were aligned to the genomic template and 
verified using Vector NTi Advance and AlignX.
Northern Blot Analysis
Total RNA was isolated from each cell line with 
TRIzol and concentrated. Aliquots of RNA (20 μg 
per sample) were mixed with equal volumes of 2× 
NorthernMax-Gly Loading Dye (with ethidium bromide), 
heated at 50°C for 30 min, and resolved on a 1% glyoxal 
agarose gel run at 65 V for 2 h 20 min in 1× running 
buffer. The gel was transferred to a nylon membrane 
(BrightStar Plus, Ambion) using downward capillary 
transfer, crosslinked using a UVP UV crosslinker at 
1200 (UVP HL-2000 HybriLinker), prehybridized for 
30 min at 42°C in 6 ml ULTRAhyb (Ambion), and then 
probed overnight at 42°C. Blots were processed with the 
BrightStar BioDetect kit (Ambion) and exposed to film. 
The following biotin-labeled DNA probes (IDT) were 
used at 166 nM: SPRY4-IT1, ctccactgggcatattctaaaa; 
SPRY4 Exon 1, gatgttgcaaccactgcctgg; SPRY4 
Exon 3, catggctggtcttcacctggtc; and GAPDH, 
gggccatgaggtccaccaccc.
Invasion Assay
A375 cells were trypsinized and reverse transfected 
using RNAiMax (Life Technologies) with 50 μM of the 
following siRNAs (Life Technologies): SPRY4-IT1 Stealth 
RNAi 594, SPRY4 Exon 1 Custom Select siRNA, lipin 2 
Silencer Select siRNAs s18590 and s18591, and Universal 
Negative control (Cat #46-2001). 
BD BioCoat™ Matrigel™ Invasion Chambers 
(24-well plates) were prepared by rehydrating the 
BD Matrigel™ matrix coating with 0.5 ml of serum-
free Complete Tu medium for 2 h at 37°C in a 5% 
CO2 atmosphere. After rehydration, the solution was 
removed and 0.5 ml of Complete Tu medium containing 
chemoattractant (2% FBS) was added to the lower wells, 
and 0.5 ml of serum-free Complete Tu medium containing 
5 × 104 A375 cells transfected with siRNAs was added 
to the insert wells. Invasion assay plates were incubated 
for 2 days at 37°C in a humidified 5% CO2 atmosphere. 
Non-invading cells were removed by scrubbing the upper 
surface of the insert, and invading cells on the lower 
surface of the insert were stained with crystal violet. 
Each membrane was mounted on a microscope slide for 
visualization and analysis. Slides were scanned using a 
Scanscope digital slide scanner, and the migrated cells 
were enumerated using Aperio software. All experiments 
were performed with biological triplicates.
Apoptosis Assay
A375 cells were trypsinized and reverse transfected 
with siRNAs as described above. Caspase activity was 
measured using the Caspase-Glo® 3/7 Assay kit (Promega) 
according to the manufacturer’s recommendations, and 
samples were read on a GloMax luminometer (Promega).
Polysome Fractionation
Cells grown in 10 cm dishes were gently removed 
with PBS and collected by centrifugation for 4 min at 100 
× g. The cell pellet was resuspended in 500 μl of lysis 
buffer (100 mM KCl, 50 mM Tris-HCl pH 7.4, 1.5 mM 
MgCl2, 1 mM dithiothreitol (DTT), 1 mg/ml heparin, 
1.5% NP-40, 100 μM cycloheximide, 1% aprotinin, 1 mM 
AEBSF, and 100U/ml of RNasin) and incubated on ice 
for 15 min. The lysate was centrifuged at 1000 × g and 
the infranatant lysate was removed from underneath the 
“fat cake”. The nuclei were pelleted by centrifugation 
in a microfuge for 10 min at 12,000 rpm. The resulting 
supernatant was carefully removed and applied to the top 
of a 15–60% sucrose gradient (in 100 mM KCl, 5 mM 
MgCl2, 20 mM HEPES pH 7.4, and 2 mM DTT). The 
gradients were centrifuged at 35,000 rpm for 3.5 h at 4°C 
in a Beckman SW41 rotor. Samples containing (i) free 
(unbound) mRNA, ribosomal subunits, and monosomes, 
and (ii) polysomes were recovered from the gradients 
using a Brandel density gradient fractionator equipped 
with an ISCO UA-6 flow cell set to 254 nm (a 70% 
sucrose solution containing orange G was slowly pumped 
into the bottom of the tube to displace the contents from 
top to bottom). Fractions were collected directly into an 
equal volume of TRIzol for isolation of RNA. The purity 
and integrity of RNA was determined with an Agilent 
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Bioanalyzer prior to analysis by northern blotting.
Affinity Purification of Endogenous SPRY4-IT1
A375 cells (108 per sample) were grown to 80-
90% confluency, the medium was discarded, and the 
plates were washed with PBS. The cells were trypsinized, 
pelleted at low speed, washed with PBS, and resuspended 
in 90 ml PBS (~106 cells/ml). Cells were crosslinked 
by incubation in 1% formaldehyde at RT with rotation, 
and then quenched by the addition of glycine to a 
final concentration of 375 mM for 5 min. The cells 
were centrifuged at low speed, washed in PBS, and 
recentrifuged. The pellet was resuspended in Buffer A 
(1% NP-40, 1 mM DTT), homogenized, and spun at low 
speed. The pellet was resuspended in nuclei lysis buffer 
(1 mM DTT, 1× protease inhibitor, and 2 μl RNaseOut) 
at a volume of 1ml per 25 × 106 cell equivalents. The 
lysate was incubated on ice, sonicated to yield 100-500 bp 
fragments (Duty Cycle, 20%; intensity, 10; cycles/burst, 
200; and time, 8 min), and then centrifuged at high speed. 
The supernatant was removed and mixed with 0.5 M 
LiCl2, then 500 pmol/25 × 10
6 cell equivalents of a SPRY4-
IT1 probe was added, and the sample was incubated at 
37°C for 24 h. The probe consisted of a 25-bp sequence 
complementary to SPRY4-IT1 constructed with a locked 
nucleic acid (LNA) backbone and a 5′-biotin label. Control 
samples contained probes complementary to the test probe 
sequence. A 2 ml aliquot of streptavidin-coated Dynabeads 
(Life Technologies) was washed twice with water and 
once with hybridization buffer, and then blocked with 800 
μg yeast tRNA and 800 μg BSA for 1 h at 37°C. The beads 
were pelleted, washed twice in nuclear lysis buffer, and 
resuspended in 2 ml of the same buffer. Prepared beads 
were added to the nuclear lysate (125 μl per 500 pmol of 
probe), rotated at 37°C, and then washed twice in 1 ml 
nuclear lysis buffer and twice in 1 ml wash buffer (5 mM 
Tris-HCl pH 7.5, 0.5 mM EDTA, 1M NaCl). Beads from 
replicate samples were combined, washed twice in PBS, 
resuspended in PBS, incubated at 75°C for 5 min, and 
applied to a magnet. The isolated beads were incubated at 
65°C overnight to reverse crosslinking, treated with 1 μg/
ml RNase A, vortexed, and incubated at RT. The samples 
were then treated with proteinase K, resuspended in Buffer 
AL, and incubated at 56°C. Finally, RNA in the complexes 
was purified using the DNeasy Kit, eluted in RNase-free 
H2O, and qRT-PCR was performed to quantify SPRY4-IT1. 
The RNA-protein complexes were then subjected to LTQ 
Orbitrap Velos MS for analysis of SPRY4-IT1–associated 
proteins. Protein digestion, TiO2-based phosphopeptide 
enrichment, and ESI-MS/MS was performed at the 
proteomics core facility at Sanford-Burnham. Table S1 
lists the identified SPRY4-IT1–binding proteins. RNA co-
immunoprecipitation (RIP) was performed as previously 
described [36]. Lipin-2 antibody H-160 was from Santa 
Cruz (sc-134433).
Real-time qRT-PCR
Quantitative PCR was carried out using 
TaqMan mRNA or SYBR Green mRNA assays 
with a 7500 Real-Time PCR System (Applied 
Biosystems/Life Technologies), in accordance with 
the manufacturer’s protocols. SDS1.2.3 software 
(Applied Biosystems) was used for comparative Ct 
analysis, with 18S rRNA serving as the endogenous 
control. Primers for SYBR qPCR were as follows: 
SPRY4-IT1 qPCR For, gctgagctggtggttgaaaggaatc; 
SPRY4-IT1 qPCR Rev, gcttggcccacgatgacttgg; 
SPRY4 Exon 1 qPCR For, ggcagtggttgcaacatcgccg; 
SPRY4 Exon 1 qPCR Rev, tagccgccgctgtactcgcagac; 
LPIN2 qPCR For, cgtctaagcagcccttctatgctgc; LPIN2 
qPCR Rev, acatgctccacgagctcactcagc; LPIN1 qPCR 
For, ggagagctggtacaggaacatgcaaag; LPIN1 qPCR 
Rev, gcagtggctctctccaaaaggtgaag; GPAT3 qPCR 
For, caaggaggcctgactgaacttccc; GPAT3 qPCR 
Rev, ccgtcctcttagctgagagatccattg; DGAT1 qPCR 
For, caacaaggacggagacgccgg; DGAT1 qPCR Rev, 
gatgccacggtagttgctgaagcc; DGAT2 qPCR For, 
ctgcactgattgctggctcatcg; and DGAT2 qPCR Rev, 
gaaagtagcgccacacagcccag.
RNA-FISH Analysis
RNA-FISH was performed using an LNA-
modified probe for human SPRY4-IT1 (5′-Texas Red-
TCCACTGGGCATATTCTAAAA) and a RiboMap in 
situ hybridization kit (Ventana Medical Systems, Inc.) on 
a Ventana machine. SPRY4-IT1-EE and vector-only cells 
were resuspended at 105 cells/ml, and 100 µl was added 
to separate cloning rings on an autoclaved glass slide. The 
following day, the rings were removed, and the slide was 
washed in PBS and fixed in 4% paraformaldehyde and 
5% acetic acid. After acid treatment using hydrochloride-
based RiboClear reagent (Ventana Medical Systems) for 
10 min at 37°C, the slide was treated with the ready-to-
use protease 3 reagent, and subjected to a denaturing pre-
hybridization step for 4 min at 80°C. The cells were then 
hybridized with 40 nM LNA-modified probe in RiboHybe 
hybridization buffer (Ventana Medical Systems) for 2 h 
at 58°C. The slide was washed 3 times for 4 min at 60°C; 
once at low stringency with 0.1× SSC (Ventana Medical 
Systems) and twice with 1× SSC. The slides were fixed 
in RiboFix and counterstained with DAPI in an antifade 
reagent (Ventana Medical Systems). Images were acquired 
using a Nikon A1R VAAS laser confocal microscope. 
5′ RACE for SPRY4-IT1
5′ RACE was performed using the FirstChoice® 
RLM-RACE (RNA Ligase-Mediated RACE) kit 
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(Ambion, Life Technologies). Total RNA was isolated 
from A375 cells with TRIzol, and 1 μg per sample was 
ligated to the 5′ RACE adapter using T4 RNA Ligase. 
This sample was then reverse transcribed using M-MLV 
reverse transcriptase. The samples were not treated with 
either calf intestinal alkaline phosphatase or tobacco acid 
pyrophosphatase and mRNA molecules thus retained both 
the 5′ 7-methyl cap and the 5′ phosphate. Multiple reverse 
primers were designed within the SPRY4-IT1 sequence to 
complement the forward 5′ RLM-RACE primers. PCR 
reactions were performed using Phusion polymerase 
(Finnzymes), run out and purified from agarose gels, and 
cloned into pCR4-TOPO (Life Technologies) for sequence 
evaluation (Retrogen). The SPRY4-IT1 RACE product 
was successfully acquired using the 5′ RACE inner 
primer (supplied with the FirstChoice® kit) and 5′ RACE 
SPRY4-IT1 reverse primer, residing 385 bp into SPRY4-
IT1 (ctctctggggacgatgcagcatccgatgg). 
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